

Depicting the cellular architecture of the tumour microenvironment by integrating hyperplex immunofluorescence and automated image analysis

I. Nearchou¹, J. Kowal², F. Rivest², A. Ortiz¹, D. Bowman¹, B. Pelz², and D. Dupouy²

¹Indica Labs Inc., Pharmaceutical Services, Albuquerque, New Mexico, United States.


²Lunaphore Technologies SA, Research and Development, Tolochenaz, Switzerland.

BACKGROUND


The tumour microenvironment (TME) is emerging as an important factor that shapes the dynamic of the tumour growth, its heterogeneity, and response to therapies⁽¹⁾. Thus, efforts are undertaken to understand better the biology of cells within the TME⁽²⁾ and to provide spatial mapping of TME components and their interactions⁽³⁾. In this study, we focus on the phenotyping of cells across different tumour types on a tissue microarray (TMA) with an immuno-oncology panel encompassing 20 biomarkers. We interrogated their TME with the use of the COMET™ automated staining and imaging instrument⁽⁴⁾, and HALO® and HALO AI™ image analysis platforms.

20plex panel includes:FoxP3, CD68, aSMA, CD31, CD38, Ido-1, s100, CD11c, PD-L1, Ki67, CD8, PD-1, CD4, PanCK, CD3, CD20, CD16, HLA-DR, Vimentin, CD45


COMET™ WORKFLOW




HALO® and HALO AI™ IMAGE ANALYSIS WORKFLOW



PROXIMITY ANALYSIS



INFILTRATION ANALYSIS



CONCLUSIONS

Tumour microenvironment (TME) composition was depicted as important regulator of the response to treatment and patient prognosis (5). Significant efforts are continuously carried out to better understand how tumors affect their surrounding by recruiting healthy cells to their proximity and interfering with their functional states. Hyperplex immunofluorescence enables interrogating TME in the manner, where complex phenotypes can be identified within the spatial context of the tissue, empowering researchers to understand better intercellular interactions and tissue-intrinsic biology (3). Current state-of-art methodologies allowing questioning proteomic composition of TME at large scale are costly in terms of time and resources to execute both experiments and data analyses, limiting the adoption and day-to-day use of hyperplex immunofluorescence.

The workflow presented here highlights the easiness of adoption of seqIF™ protocol and a supervised image analysis pipeline. COMET™ platform ensures single-cell resolution and the simultaneous detection capability of multiple protein biomarkers with high reproducibility. COMET™ automates all steps of protocol execution and limits inter-experiments variability, while using standard reagents and delivering 20 20-plex images in 1 week. We demonstrate further how the combination of COMET™ hyperplex images with the HALO® and HALO AI™ image analysis platform from Indica Labs, results in an easy and straightforward workflow for interrogating heterogeneous TME and depicting tissue architecture on the single-cell level. HALO® and HALO AI™ enable guided and automated data extraction from hyperplex images with flexible workflow design. Our analysis of a 20-plex immuno-oncology panel on a TMA containing invasive breast carcinoma cores and colon adenocarcinoma cores yielded several insights into the cellular phenotypes and complex spatial relationships in the TME including T lymphocytes and macrophages. We were able to demonstrate distinct tumour infiltration patterns and characterize the accumulation of immune cells in the stroma and tumor compartment.

COMET™ images, together with HALO® and HALO AI™, can be directly used for quantitative analysis of the TME, enabling researchers the identification of the biomarkers across different tumors and at a single-cell level. The high throughput of COMET™ together with HALO® and HALO AI™ workflows stand out as tools that allow bringing the hyperplex immunofluorescence to every laboratory and streamlines the study of TME across basic and translational research.

REFERENCES

(1) Binnewies, M., Roberts, E.W., Korsten, K. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24, 541–559 (2018). <https://doi.org/10.1038/s41591-018-0014-x>

(2) Rao, A., Barkley, D., France, C.S. et al. Exploring tissue architecture using spatial transcriptomics. Nature 596, 211–220 (2021). <https://doi.org/10.1038/s41586-021-02834-9>

(3) Lewis, S.M., Asselin-Labat, M.L., Nguyen, Q. et al. Spatial omics and multiplexed imaging to explore cancer biology. Nat Methods 18, 997–1012 (2021). <https://doi.org/10.1038/s41592-021-01203-6>

(4) Migliozi, D., Pelz, B., Dupouy, D.G. et al. Microfluidics-assisted multiplexed biomarker detection for in situ mapping of immune cells in tumor sections. Microscyst Nanoeng 5, 59 (2019). <https://doi.org/10.1038/s41378-019-0104-z>

(5) Hanahan D and Weinberg RA. Hallmarks of Cancer: The Next generation. Cell 5 :144 (2011). <https://doi.org/10.1016/j.cell.2011.02.013>